Time filter

Source Type

Rotterdam, Netherlands

Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2007-2.3.3-9 | Award Amount: 15.97M | Year: 2009

The EMPERIE (European Management Platform for Emerging and Re-emerging Infectious disease Entities) consortium has its roots in the lessons learned by the majority of the participating centres during the recent SARS and HPAI H5N1 outbreaks. The mission of EMPERIE is to contribute to effectively countering the potential public health threat caused by new and emerging infectious diseases in Europe by establishing a powerful network capable of structural and systematic prediction, identification, modelling and surveillance of infectious diseases health threats and pathogens. In pursuit of this mission EMPERIE will establish a network of centres of excellence combining the expertise, techniques and resources necessary for effectively countering (re)-emerging infectious diseases. We will establish common processes, procedures and communication channels in the network linked to relevant stakeholder organisations and local grass root sites to contribute to a structural and systematic prediction, identification, modelling and surveillance of (re-)emerging infectious disease health threats and pathogens. Our focus will be new zoonotic viruses that may cause epidemics and viruses already present but yet unrecognised- in humans. Within this focus, we will attain proof of principle of the functioning of the network and the techniques, systems, procedures and resources in the following RNA viruses: Flaviviruses (e.g. Dengue, West-Nile virus), Alphaviruses (e.g. Chikungunya), Orthomyxoviruses (e.g. Influenza), Paramyxoviruses (e.g Henipah,) Coronaviruses, Bunyaviruses ( e.g. hantavirus) and Filoviruses

The amount of the deal was not disclosed. Founded in 2001 as a spin-off from the virology department at the Erasmus Medical Centre in Rotterdam, the Netherlands, and led by Bob van Gemen, CEO, Viroclinics Biosciences BV is a virology contract research organization, serving the biopharmaceutical community as a pre-clinical and clinical reference laboratory for supporting the development of new chemical entities, vaccines and antiviral compounds targeting viral infectious diseases. At the start of 2013, it opened a samples processing facility in Boston USA. With the transaction, the founding institute Erasmus University Medical Center (Erasmus MC) exited the company. Viroclinics intends now to use the proceeds to expand service its offering and plans to continue its collaboration with the Viroscience lab of Erasmus MC and co-develop new laboratory services in the field of virology.

Reusken C.B.E.M.,National Health Research Institute | Haagmans B.L.,Erasmus Medical Center | Muller M.A.,University of Bonn | Gutierrez C.,University of Las Palmas de Gran Canaria | And 25 more authors.
The Lancet Infectious Diseases | Year: 2013

Background: A new betacoronavirus-Middle East respiratory syndrome coronavirus (MERS-CoV)-has been identified in patients with severe acute respiratory infection. Although related viruses infect bats, molecular clock analyses have been unable to identify direct ancestors of MERS-CoV. Anecdotal exposure histories suggest that patients had been in contact with dromedary camels or goats. We investigated possible animal reservoirs of MERS-CoV by assessing specific serum antibodies in livestock. Methods: We took sera from animals in the Middle East (Oman) and from elsewhere (Spain, Netherlands, Chile). Cattle (n=80), sheep (n=40), goats (n=40), dromedary camels (n=155), and various other camelid species (n=34) were tested for specific serum IgG by protein microarray using the receptor-binding S1 subunits of spike proteins of MERS-CoV, severe acute respiratory syndrome coronavirus, and human coronavirus OC43. Results were confirmed by virus neutralisation tests for MERS-CoV and bovine coronavirus. Findings: 50 of 50 (100%) sera from Omani camels and 15 of 105 (14%) from Spanish camels had protein-specific antibodies against MERS-CoV spike. Sera from European sheep, goats, cattle, and other camelids had no such antibodies. MERS-CoV neutralising antibody titres varied between 1/320 and 1/2560 for the Omani camel sera and between 1/20 and 1/320 for the Spanish camel sera. There was no evidence for cross-neutralisation by bovine coronavirus antibodies. Interpretation: MERS-CoV or a related virus has infected camel populations. Both titres and seroprevalences in sera from different locations in Oman suggest widespread infection. Funding: European Union, European Centre For Disease Prevention and Control, Deutsche Forschungsgemeinschaft. © 2013 Elsevier Ltd. Source

Smits S.L.,Viroclinics Biosciences
Emerging infectious diseases | Year: 2013

To identify unknown human viruses, we analyzed serum and cerebrospinal fluid samples from patients with unexplained paraplegia from Malawi by using viral metagenomics. A novel cyclovirus species was identified and subsequently found in 15% and 10% of serum and cerebrospinal fluid samples, respectively. These data expand our knowledge of cyclovirus diversity and tropism. Source

Hillaire M.L.B.,Erasmus Medical Center | Osterhaus A.D.M.E.,Erasmus Medical Center | Osterhaus A.D.M.E.,Viroclinics Biosciences | Rimmelzwaan G.F.,Erasmus Medical Center | Rimmelzwaan G.F.,Viroclinics Biosciences
Journal of Biomedicine and Biotechnology | Year: 2011

There is considerable interest in the development of broadly protective influenza vaccines because of the continuous emergence of antigenic drift variants of seasonal influenza viruses and the threat posed by the emergence of antigenically distinct pandemic influenza viruses. It has been recognized more than three decades ago that influenza A virus-specific cytotoxic T lymphocytes recognize epitopes located in the relatively conserved proteins like the nucleoprotein and that they cross-react with various subtypes of influenza A viruses. This implies that these CD8 + T lymphocytes may contribute to protective heterosubtypic immunity induced by antecedent influenza A virus infections. In the present paper, we review the evidence for the role of virus-specific CD8 + T lymphocytes in protective immunity against influenza virus infections and discuss vaccination strategies that aim at the induction of cross-reactive virus-specific T-cell responses. Copyright © 2011 Marine L. B. Hillaire et al. Source

Discover hidden collaborations